Press release - January 24th, 2011

A new study proves the painkilling effect of transcutaneous Vagus Nerve Stimulation at man

Erlangen/Regensburg, January 24th, 2011. The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg from March to October 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

In the context of the study, 48 healthy subjects underwent quantitative sensory testing (QST) with and without t-VNS activated on different days. A comprehensive comparative analysis was made of their perception of pain and pain sensitivity.

With t-VNS, there was a statistically significant and clinically relevant lowering of the mechanical pain perception and a rise in the pressure pain threshold. “Until now, the analgesic effect of vagus nerve stimulation has only been proven in animal experiments, and only occasionally observed in people with invasive vagus nerve stimulation,” says Dr. Busch. "Now, however, for the first time, this effect could be proven with t-VNS in a randomized, controlled study in humans. The positive results point to the fact that in the future t-VNS could help soothe musculoskeletal pain and other chronic pain syndromes, such as migraine."

Chronic pain affects about 20 to 25 per cent of people today, and thus counts as one of the most common ailments in the developed world. Prof. Jens Ellrich, Chief Medical Officer at cerbomed, explains that the great potential of an alternative treatment stems mainly from the current, often inadequate approach of drug-based therapies which have many undesirable side effects: "The results and findings from this preclinical study make planning further clinical studies into the therapy of chronic pain with t-VNS possible."

cerbomed will present the full results from the study for the first time at the Joint Neuromodulation meeting of the Benelux Neuromodulation Society, taking place from January 27th to 29th, 2011 in Groningen, the Netherlands. (

About cerbomed:
cerbomed GmbH is an innovative medical device company, that concentrates on researching, developing and producing new technologies and products for neuromodulation. The company’s focus is on transcutaneous Vagus nerve stimulation (t-VNS), which offers an attractive therapy alternative for patients with hard to treat neurological and psychiatric illnesses.
In March 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus nerve stimulator NEMOS. An international multicenter study is currently in planning to measure the effectiveness of t-VNS in patients with drug-resistant epilepsy.

pdf Download Article

Please note: NEMOS® is not cleared or approved for use in the U.S.